Word: heartburned
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...being able to come to Little Rock and preach tax cuts while I preach a tax increase," Huckabee told TIME. "He has a tool that I do not have, called deficit spending, and can shift--or at least not fix--the Medicaid issue, which is causing most of my heartburn." Medicaid costs in Arkansas have risen from $1.2 billion a decade ago to $2 billion, and Huckabee, like Governors everywhere else, wants Washington to start shouldering more of the burden...
...face, the Herald Tribune wouldn't seem worth the heartburn. It sells just 264,000 copies, spread thinly over 180 countries. Investors were happy to see Graham shed the money loser; the Washington Post Co.'s shares rose on the news. "Who cares about it except some guy in a bar in France?" said Ed Atorino, newspaper analyst at Blaylock & Partners...
...core business, pharmaceuticals is very risky." Some observers think Procter should stick to the over-the-counter business, leveraging its marketing savvy and retail relationships to help bigger pharma companies roll out nonprescription versions of their drugs, as it is doing with Astra Zeneca for its heartburn medication, Prilosec. Fortunately, at least for the moment, Lafley shouldn't have much need for that kind of remedy. --With reporting by Daren Fonda/New York
...know? Suffice it to say I've spent a good deal of time over the last ten years either on Amtrak trains or desperately trying to avoid the Amtrak experience. At best, my train trips have been tolerable. At worst, they've given me the kind of heartburn that only comes from four hours of pent-up rage...
...wonder drugs in today's medical arsenal, the heartburn treatment Prilosec has long been the most successful. The stomach soother reaped an astonishing $6.2 billion in sales last year to make it the best-selling prescription drug ever--a title Prilosec stands to lose when its patent expires in October. But if the drug's maker, British firm AstraZeneca, behaves like many of its counterparts in the industry, it won't easily relinquish its monopoly. Indeed, sources confirmed to TIME that the Federal Trade Commission has quietly launched an investigation into whether AstraZeneca illegally blocked generic competition to protect...